We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pocket-Sized Devices Enable Real-Time DNA and RNA Sequencing Anywhere

By LabMedica International staff writers
Posted on 05 Jul 2022

DNA and RNA sequencing can answer a range of biological questions, providing information on pathogen identity, genetic disease risk or how an organism has evolved. More...

Now, a new generation of sensing technology uses nanopores - nano-scale holes - embedded in high-tech electronics, to perform precise molecular analyses in fully scalable formats from pocket to population-scale devices. The advantages of real-time sequencing include rapid access to time critical information (e.g. pathogen identification), the generation of early sample insights and more control over the sequencing experiment.

The new generation of DNA/RNA sequencing technology developed by Oxford Nanopore Technologies (Oxford, UK) is the only sequencing technology that offers real-time analysis (for rapid insights), in fully scalable formats from pocket to population scale, and can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. All Oxford Nanopore sequencing devices use flow cells which contain an array of tiny holes - nanopores - embedded in an electro-resistant membrane. Each nanopore corresponds to its own electrode connected to a channel and sensor chip, which measures the electric current that flows through the nanopore. When a molecule passes through a nanopore, the current is disrupted to produce a characteristic ‘squiggle’. The squiggle is then decoded using basecalling algorithms to determine the DNA or RNA sequence in real time.

Oxford Nanopore has opened up RNA/DNA sequencing to anyone, anywhere in small formats such as Flongle which addresses the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. Similarly, the pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long read sequence data. On the other hand, the benchtop GridION Mk1 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. In addition, PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – capable of delivering more than 10 Tb of sequence data in a full run, and is now being used in population-scale sequencing projects.

The company has also launched PromethION 2 (P2) solo, a first-in-class handheld, low-cost, ultra-high-throughput DNA sequencing device. Designed to deliver high-output, low-cost sequencing in a palm-sized device and make high-throughput sequencing more accessible, the P2 supports users wishing to discover more, rich biological insights about human disease, including cancer and ultra-long plant and animal genomes or larger transcriptome/metagenomic analyses. The new device can produce as much as 580 Gb sequence data in one run.

Related Links:
Oxford Nanopore Technologies 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.